dc.contributor.author |
Yakovlev I. |
|
dc.contributor.author |
Deev R. |
|
dc.contributor.author |
Rizvanov A. |
|
dc.contributor.author |
Isaev A. |
|
dc.date.accessioned |
2018-09-19T23:00:00Z |
|
dc.date.available |
2018-09-19T23:00:00Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
2191-1630 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/145896 |
|
dc.description.abstract |
© 2016, Springer Science+Business Media New York.Due to lack of effective therapies, muscular dystrophies became a focus for gene therapy. Multiple pre-clinical studies have shown successful restoration of dystrofin and dysferlin by RNA editing both in vivo and in vitro, but possibility of a clinical translation is still obscure. A number of new chemicals are being studied, and a search for new techniques is ongoing. This work is intended to give a brief overview of the current state of the RNA editing for treating muscular dystrophies. |
|
dc.relation.ispartofseries |
BioNanoScience |
|
dc.subject |
Duchenne muscular dystrophy |
|
dc.subject |
Dysferlinopathy |
|
dc.subject |
Exon skipping |
|
dc.subject |
RNA editing |
|
dc.subject |
Trans-splicing |
|
dc.title |
RNA Editing for Muscular Dystrophy Therapy |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
2 |
|
dc.relation.ispartofseries-volume |
7 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
386 |
|
dc.source.id |
SCOPUS21911630-2017-7-2-SID85019131481 |
|